Evidence mapPaperPMID 39199348Full record

ReviewBiomolecules2024

Biomembrane-Modified Biomimetic Nanodrug Delivery Systems: Frontier Platforms for Cardiovascular Disease Treatment.

Yunan Gu, Lixin Du, Yuxin Wu, Juan Qin, Xiang Gu, Zhihua Guo, Ya Li

Abstract readReview
In one paragraph

Review in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Biomimetic materials for medical applications.Chinese medical journal · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. How Advanced Is Nanomedicine for Atherosclerosis?International journal of nanomedicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yunan GuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Lixin DuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Yuxin WuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Juan QinSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Xiang GuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Zhihua GuoSchool of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.
Ya LiSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0009-0005-8684-9308

Funding

Hunan University students innovation and entrepreneurship training program S202310541090Key Discipline Project on Chinese Pharmacology of Hunan University of Chinese Medicine 202302National Natural Science Foundation of China 82174343Postgraduate Scientific Research Innovation Project of Hunan Province CX20230830Scientific Research Topics of Hunan Provincial Health and Wellness Commission D202303017861
6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) are one of the leading causes of death worldwide. Despite significant advances in current drug therapies, issues such as poor drug targeting and severe side effects persist. In recent years, nanomedicine has been extensively applied in the research and treatment of CVDs. Among these, biomembrane-modified biomimetic nanodrug delivery systems (BNDSs) have emerged as a research focus due to their unique biocompatibility and efficient drug delivery capabilities. By modifying with biological membranes, BNDSs can effectively reduce recognition and clearance by the immune system, enhance biocompatibility and circulation time in vivo, and improve drug targeting. This review first provides an overview of the classification and pathological mechanisms of CVDs, then systematically summarizes the research progress of BNDSs in the treatment of CVDs, discussing their design principles, functional characteristics, and clinical application potential. Finally, it highlights the issues and challenges faced in the clinical translation of BNDSs.

Indexed as

Cardiovascular DiseasesDrug Delivery SystemsAnimalsBiomimetic MaterialsBiomimeticsHumansNanomedicineNanoparticle Drug Delivery SystemNanoparticlesNanoparticle Drug Delivery Systembiomembranebiomimetic nanodrug delivery systemscardiovascular diseasestargeting

Identifiers

PMID39199348
PMCPMC11352341

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.